Clinical Practice of Photodynamic Therapy Using Talaporfin Sodium for Esophageal Cancer

Photodynamic therapy (PDT) using a conventional photosensitizer was approved for esophageal cancer in the early 1990s; however, it was replaced by other conventional treatment modalities in clinical practice because of the high frequency of cutaneous phototoxicity and esophageal stricture after the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2021-06, Vol.10 (13), p.2785
Main Authors: Yano, Tomonori, Minamide, Tatsunori, Takashima, Kenji, Nakajo, Keiichiro, Kadota, Tomohiro, Yoda, Yusuke
Format: Article
Language:English
Subjects:
Ablation
Clinical medicine
Cytotoxicity
Drug dosages
Endoscopy
Esophageal cancer
Lasers
Light
Lung cancer
Photodynamic therapy
Review
Skin
Sodium
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Photodynamic therapy (PDT) using a conventional photosensitizer was approved for esophageal cancer in the early 1990s; however, it was replaced by other conventional treatment modalities in clinical practice because of the high frequency of cutaneous phototoxicity and esophageal stricture after the procedure. The second-generation photosensitizer, talaporfin sodium, which features more rapid clearance from the body, was developed to reduce skin phototoxicity, and talaporfin sodium can be excited at longer-wavelength lights comparing with a conventional photosensitizer. Endoscopic PDT using talaporfin sodium was initially developed for the curative treatment of central-type early lung cancer in Japan, and was approved in the early 2000s. After preclinical experiments, PDT using talaporfin sodium was investigated for patients with local failure after chemoradiotherapy, which was the most serious unmet need in the practice of esophageal cancer. According to the favorable results of a multi-institutional clinical trial, PDT using talaporfin sodium was approved as an endoscopic salvage treatment for patients with local failure after chemoradiotherapy for esophageal cancer. While PDT using talaporfin sodium is gradually spreading in clinical practice, further evaluation at the point of clinical benefit is necessary to determine the importance of PDT in the treatment of esophageal cancer.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm10132785